Journal of Applied Pharmaceutical Science Vol. 11(09), pp 009-017, September, 2021
Available online at http://www.japsonline.com
DOI: 10.7324/JAPS.2021.110902
ISSN 2231-3354
Factors affecting purchasing behaviors of generic drugs versus
originator counterparts in Jordan
Maha N. Abu Hajleh1*, Ali AL-Samydai2, Zahraa Aloosi3, Raghad Abuhamdan3, Sumaiah Al.Naimat3, Lina Abdelfattah3,
Lidia Al-Halaseh4
1
Department of Cosmetic Science, Pharmacological and Diagnostic Research Centre, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University,
Amman, Jordan.
2
Pharmacological and Diagnostic Research Centre, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan.
3
Faculty of Pharmacy, The University of Jordan, Amman, Jordan.
4
Department of Pharmaceutical Chemistry, Faculty of pharmacy, Mutah University, Al-Karak, Jordan.
ARTICLE INFO
ABSTRACT
Received on: 23/04/2021
Accepted on: 28/06/2021
Available online: 05/09/2021
Background: The use of generic drugs is increasing in several countries due to their lower price while maintaining the
same efficacy as their originator counterparts. But some concerns arise from the lack of knowledge or misunderstanding
of the concept of bioequivalence and/or from manufacturers’ marketing efforts that lead consumers to switch back to
branded drugs.
Method: A random sample of 350 percipients has been enrolled; 304 had completed the questionnaire that was used
in this study (regarding the factors influencing consumers’ preferences for generic vs. branded drugs). The forms have
been distributed online (using Google Form) among all participants.
Results: Results revealed that the most influential factor for participants when purchasing drugs was the role of the
pharmacist. Lack of knowledge about the efficacy of drugs has the lowest effect on choosing the medication. Also,
the price and confidence in brand-name drugs showed a statistically significant effect on selecting the medications.
Conclusion: Generic drugs seem to be the best option for patients but a progressive alteration is required in people’s
mentality to accept this fact. This can be done through promoting educational interferences to increase consumer and
health system confidence in the capability of generic medications to treat chronic diseases.
Key words:
Bioequivalence, generic
drugs, originator counterparts,
economic benefits,
purchasing/prescription
behaviors.
INTRODUCTION
Regarding bioequivalence, two pharmaceutical products
are considered to be bioequivalent in their bioavailabilities (rate
and extent) and efficacies if they are administered in identical
amounts of the same active substance(s), similar dosage forms,
and same route of administration and if they display comparable
properties (Dunne et al., 2013). Therefore, generic drugs are
permitted by regulators based on evidence of pharmaceutical
equivalence and bioequivalence with the originator counterparts.
*
Corresponding Author
Maha Abu Hajleh, Department of Cosmetic Science, Pharmacological
and Diagnostic Research Centre, Faculty of Allied Medical Sciences,
Al-Ahliyya Amman University, Amman, Jordan.
E-mail: mahaabuhajleh @ hotmail.com
The excipients of the originator and generic drugs are not
necessarily similar, which may affect the pharmacokinetics and
pharmacodynamics parameters of the drug and its safety profile.
According to the World Health Organization, a generic drug is
a pharmaceutical product that is produced by a manufacturer
without a license from the patent-holding company and marketed
when the original patent has expired, which means that they do
not need the originator company’s approval to produce a generic
drug (Dunne et al., 2013; US Food and Drug Administration,
2013). Also, they contain equivalent quantities and qualities of
the same active substance(s) and the same pharmaceutical form
as their reference original drugs, with low-cost price, and may
contain different excipients (Desai et al., 2019; Kesselheim
et al., 2008; Vogler, 2012). However, bioequivalence and the
role of excipients may be elucidated regarding the clinical
efficacy and safety when switching from originator to generic
© 2021 Maha N. Abu Hajleh et al. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License
(https://creativecommons.org/licenses/by/4.0/).
010
Hajleh et al. / Journal of Applied Pharmaceutical Science 11 (09); 2021: 009-017
formulations. Cost-benefits, purchasing, and prescription
behaviors can explain the choice between generic and originator
counterparts (Gallelli et al., 2013). The use of generic drugs
is trending upward in the upcoming years, accounting for
approximately 90% of all prescriptions drug in the US (Desai
et al., 2019). The definitive aim of generic drug production is to
enhance the global access and regulation of generic drugs and
to preclude drug shortages and supply disturbances (Håkonsen
and Toverud, 2019). Likewise, many consumers and providers
recognize generic drugs to be less effective and less safe than
their originator counterparts (Kesselheim et al., 2016). These
negative expectations may affect patients to experience negative
clinical results while using generic drugs (Desai et al., 2019).
Once the generic drug enters the market, an increase in cost
savings is highly probable. In comparison to the originator,
the use of generic drugs has a significant economic benefit in
controlling healthcare spending and saving money for society.
Thus, a true economic cost must be carefully considered before
switching a drug, taking into account the clinical outcomes of
the generic medication for any individual patient (Dunne et al.,
2013; Johnston et al., 2010; Olsson and Sporrong, 2012).
In 2005, a health economic study examined the possible
cost savings for the substitution of originator drugs with generic
drugs based on data collected from 1997 to 2000. It showed
that generic substitutions could save up to 5.9 billion dollars for
populations younger than 65 years old and 2.9 billion dollars for
populations older than 65 years old (Haas et al., 2005; Rizzo
and Zeckhauser, 2009). Thus, generic drugs offer healthcare
systems considerable cost savings; however, their acceptance is
stalled by worries of physicians and patients about the efficacy
and safety of these drugs (Tian et al., 2020). Many factors can
affect the prescriptions/purchasing behavior of the bioequivalent
medication (Rizzo and Zeckhauser, 2009). Physicians are
the eventual decision-makers of which drug brands should
be prescribed to their patients. Therefore, all the marketing
strategies are being directed toward them (Ahmed et al., 2020;
Shamim-ul-Haq et al., 2014). Their decisions have a profound
impact on the quantity, quality, and costs of healthcare systems
(Mohammadshahi et al., 2019). There are specific factors that
affect the prescription attitude of physicians such as a new drug
in the market, brand prescription, sponsorship to conferences,
promotional tools, and free drug samples (Shamim-ul-Haq et
al., 2014). Shamim-ul-Haq et al. (2014) suggest that new drugs,
promotional tools, and drug samples significantly effluence the
prescription behavior of physicians, and the remaining factors
do not have any major effect. Originator products are always
expensive compared to local products; consequently, the brand
prescription is less effective on the prescription behavior of
physicians due to the cost factor, whereas Raheem Ahmed et al.
(2020) concluded that marketing elements (such as the brand
of the drug, sales promotion, availability of drug information,
medical representatives’ effectiveness, patient’s characteristics
including their expectations and request for a particular drug,
and pharmacist factors) have a positive and massive influence
on the decision of physician to prescribe a drug. Furthermore,
physician’s habits and the cost-benefit ratio of the medicine have
played a substantial moderating effect to prescribe a specific drug.
Physicians are more willing to prescribe generic medications
when a medical representative of a generic company visits
them many times per month and provides them with sufficient
information and upgrades about the generic drug (Shamim-ulHaq et al., 2014).
On the other hand, the characteristics of the drug do not
have any moderating influence on the expectations of patients
and the decisions of physicians to prescribe the drug. Similarly,
trustworthiness has a significant control impact on pharmacist–physician cooperation, the pharmacists’ expertise, and the
decision of physicians to prescribe a drug (Schumock et al.,
2004). Therefore, the financial incentives of the consumers and
physician’s influence play important roles in consumer purchasing
patterns of prescription drugs (Kohli and Buller, 2013). The main
purpose of this research was to understand what factors impact
consumers’ purchasing/prescription patterns of generic drugs
versus originator drugs and to add sufficient knowledge based on
consumer preference (Rizzo and Zeckhauser, 2009). Additionally,
the aim was to investigate the role of healthcare professionals
specifically physicians and pharmacists in the acceptance of
generic drugs since they create the ultimate decision on what to
prescribe and dispense. Also, the purpose of this research was to
display the roles of healthcare professionals in persuading patients
whose confidence in generic drugs often rests on the appropriate
information provided by health specialists (Håkonsen and
Toverud, 2019).
MATERIALS AND METHODS
Study design
This study was conducted in Jordan from March to
October of 2020. Google Form surveys were used to investigate
the factors affecting the choice between originator drugs and
generic drugs (Al-Samydai et al., 2020). A simple random
sampling strategy was used to collect data. Three hundred and
four people were recruited and their demographic data have also
been reported. To ensure the quality of the survey, we set the
response range of some items (e.g., age, marital state, academic
qualification, and field of study). Finally, a total of 304 people
who completed the questionnaires (which contained 37 questions
as shown in Appendix Table 1) were included in the analysis
(Al-Samydai et al., 2020).
Study model
Figure 1 shows the study model which contains the
study research problem, objectives, and hypotheses (Al-Samydai
et al., 2019; Yousif and Al-samydai, 2019). The hypothesis of this
study is to investigate the impact of independent factors (the role
of physician, the role of pharmacist, efficacy, price, experience,
and confidence) on the dependent factor (choice of the drug).
Statistical analysis
The study aimed to document the impact of several
factors affecting the choice of the drug. Therefore, bivariate
correlation analysis, linear regression, two-sample t-test, and
one-way analysis of variance (ANOVA) were conducted using
Statistical Package for the Social Sciences® software, version 21
(Aburjai et al., 2019). Values of p ≤ 0.05 are considered to be
significant.
011
Hajleh et al. / Journal of Applied Pharmaceutical Science 11 (09); 2021: 009-017
Table 1. Demographic distribution of the study samples.
Type
Gender
Age
Marital
status
Educational
level
Figure 1. Study model; the factors affecting the choice of the originator drug
versus generic drug. (H1): there is an impact of physician role on the choice
of the drug, (H2): there is an impact of pharmacist role on the choice of the
drug, (H3): there is an impact of efficacy on the choice of the drug, (H4): there
is an impact of price on the choice of the drug, (H5): there is an impact of
experience and information on the choice of drug, and (H6): there is an impact
of confidence on the choice of the drug.
RESULTS AND DISCUSSION
Although the use of generic drugs has augmented
promptly in the past two decades, many negative observations may
lead patients to switch back to the branded product after generic
substitution. Indeed, switching back to the branded product is
highly prevalent and their role in educating the patients about
drugs’ safety, effectiveness, price, and quality may affect patients’
perceptions (Desai et al., 2019; Kesselheim et al., 2016). Table 1
shows the demographic distribution of study samples.
The general drug purchasing patterns of Jordanian
individuals and the factors affecting their drug choice were tested
based on data collected from a random sample of the Jordanian
population. Table 2 shows the multiple regression analyses
between the role of physicians, the role of pharmacists, efficacy,
price, experience and information, and confidence in the choice
of medications. Table 2 also shows that the research-dependent
variables (choice of medications) are significant because the
p-value is 0.000 which is < 0.05, and the calculated F-value is
27.827, which is more than the table F-value (2.372). Therefore,
we reject the null hypothesis and accept the alternative one which
states that there is a statistically significant effect at the level of α
≤ 0.05 of the role of physicians, the role of pharmacists, efficacy,
price, experience and information, and confidence on the choice
of drugs. The relationship between dependent and independent
variables is strong and positive. It is > 0.5 (Cohen, 1999), R =
0.600. Also, R2 = 0.360, which means that the contribution of the
independent variables strongly affects the dependent variables
with a percentage of 36.0% since the value of the calculated
t for the variables (the role of physician: 2.470; the role of the
pharmacist: 5.834; price: 4.292; experience and information:
2.363; and confidence: 4.677) is more than the table t-value (1.96).
This means that they have a statistically significant effect on the
choice of medications, while the t-value of the efficacy was 0.435,
which was less than the table t-value (1.96), which means that the
efficacy does not have a statistically significant effect on the choice
Field of
study
Frequency
Percent
Male
99
25.5
Female
205
52.8
<30 years
146
37.6
30–35 years
93
24.0
40–50 years
40
10.3
>50 years and older
25
6.4
Single
167
43.0
Married
129
33.2
Others
8
2.1
High school
27
7
Diploma
30
7.7
Bachelor’s degree
214
55.2
Master degree
26
6.7
PhD
7
1.8
Medical sector
88
21.6
Science, engineering, and
technology sector
81
22.7
Educational, linguistic, or
social sciences or business
87
20.9
Others
48
12.4
of medications. The role of a pharmacist is considered one of the
main factors affecting drug choice, which plays a critical role in
using generic or originator counterparts. Table 3 shows that the
independent factors (effectiveness, experience and information,
the role of physician, price, confidence, and role of the pharmacist)
and dependent variable (the choice of medications) had significant
positive linear relationships of 0.173, 0.288, 0.335, 0.360, 0.362,
and 0.410, respectively.
One-way ANOVA was carried out to test the effect of
the field of study on the choice of medications. The results show
that there was a significant difference, which means that the
field of study has an impact on the choice of medications with
p = 0.023. Science and humanity field respondents showed the
highest positive correlations between dependent and independent
variables, while medical field respondents showed a negative
correlation. The main factors affecting the preference for
purchasing generic drugs were the socioeconomic factor (Guttier
et al., 2017) and this was compatible with several studies that
suggested that generic competition affects branded- prices and
market shares (Aronsson et al., 2001), and there is a strong
dynamic relationship between consumer trust and product loyalty
(Alhabeeb, 2007), where consumers’ confidence in the product
characteristics, especially those related to knowledge about
generic drugs, plays an important role in choosing the product.
Concerning age, there were no differences in the preference of
generic and branded drugs. In terms of education, nine nonmedical
field respondents or less educated individuals were more affected
by the pharmacist and physician’s opinions toward generic and
branded- drugs. Information from pharmaceutical companies
increases awareness of available medicines in the market (Davari
et al., 2018). Also, Quintal and Mendes (2012) carried out a
012
Hajleh et al. / Journal of Applied Pharmaceutical Science 11 (09); 2021: 009-017
Table 2. Results of multiple regressions of the first main hypothesis.
Dependent variable
R
R2
F
Sig.
The choice of medications
0.600
0.360
27.827
0.000
Independent
variable
Beta
t
Sig.
The role of physician
0.125
2.470
0.014
The role of
pharmacist
0.299
5.834
0.000
Effectiveness
0.022
0.435
0.664
Price
0.221
4.292
0.000
Experience and
information
0.120
2.363
0.019
Confidence
0.236
4.677
0.000
R = correlation coefficient; R2 = coefficient of determination; F = F-statistic; Sig. = significance probability (p-value ≤ 0.05: statistically
significant; p-value > 0.05 = not statistically significant); Beta = unstandardized coefficients; and t = test statistic for t-test.
Table 3. Correlations (Pearson’s correlation) between independent factors and dependent factors.
Role of
physician
Role of
pharmacist
Efficacy
Price
Experience and
information
Confidence
0.288
0.362
Overall correlation with choice of drug
0.335
0.410
0.173
0.360
Impact of age status on choice of drug
Sig.
<30 years
0.414
0.418
0.172
0.320
0.402
0.460
30–35 years
0.203
0.435
0.195
0.424
0.069
0.098
40–50 years
0.295
0.364
0.095
0.416
0.478
0.584
>50 years and older
0.420
0.276
0.167
0217
0.010
0.465
0.316
0.451
0.375
0.503
0.109
0.125
0.400
0.449
Impact of field of study on choice drug
Medical sector
0.359
0.348
0.094
0.291
Science, engineering, and
technology sector
0.417
0.454
0.268
0.439
Educational, linguistic, or
social sciences or business
0.199
0.368
0.194
0.589
Others
0.384
0.500
0.121
0.174
research on medicine use and pharmacists’ counseling; it was
observed that the lack of information received by the user, lack of
prescription, and absence of confidence in generic medicines were
the main reasons for the underuse of generic drugs. However, after
recognizing the specific knowledge about price and having better
knowledge about generic drugs, users had a higher preference for
purchasing them. A previous study conducted by Keenum et al.
(2012), which has concluded that most respondents agreed that
generic drugs were inexpensive (98%), was as effective as the
branded medicine (77%), and had no problem in replacement with
generic ones (80%), but only 45% preferred generic drugs over
the originator counterparts. Nardi and Ferraz (2016) concluded
that the price is an important factor that may contribute to the
decision to purchase generic drugs. And those who showed a
lower effect on the preference for generic drugs were efficacy
and experience, in comparison to the healthcare system’s role that
showed a higher effect. Thus, raising awareness on the quality of
generic drugs in healthcare professionals and consumers was the
best approach, especially that a physician has no direct pecuniary
incentives to choose less expensive products or overall to inform
himself/herself about generic alternatives (Aronsson et al., 2001).
Patient admittance to harmless and profitable treatment became
0.333
Sig.
0.023
a main priority in the healthcare system. The development of
bioequivalent drugs in comparison to original drugs has become
an interesting topic to both the industry and society to reduce
healthcare costs, fulfill the needs of healthcare sponsors, possibly
grow availability to patients, and patient and physician acceptance,
with numerous patients choosing biologics and branded products.
Also, physicians prescribing the same limits the use of generic
medicine and bioequivalence. The growth of generic products
depend on sponsors’ decisions to provide or use these products
safely and selflessly (Ibrahim and Awaisu, 2020). Known factors
affecting people’s behaviors toward purchasing generic drugs
versus originators will play an impotent role for many companies
to put strategies based on the market and help other companies to
enter the marketplace.
CONCLUSION
The use of generic drugs is trending upward; their usage
increases in several countries due to the lower price compared to
their originator counterparts while maintaining the same efficacy.
The results revealed that the most influential factor for participants
when purchasing drugs was the pharmacist’s role. On the contrary,
lack of knowledge about the effectiveness of drugs has the lowest
Hajleh et al. / Journal of Applied Pharmaceutical Science 11 (09); 2021: 009-017
effect on choosing the medication. Also, the price and confidence
in branded drugs showed a statistically significant impact on
selecting the medicines. It was concluded that generic medication
seems to be the best option for patients. Still, progressive alteration
is required in people’s mentality to accept this fact, which may
achieve by healthcare consumer education toward generic
medication. In addition to this, the guidance of the healthcare
system is essential for patients to switch to generic drugs from
branded products.
PROSPECTS OF THE STUDY
The growth of the generic drug market depends
on patients’ understanding of their safety and efficacy. Thus,
understanding various factors that affect people’s behaviors
toward generic drugs versus originator drugs will play an impotent
role for many generic drug manufacturing companies. It will help
them plan their policies for entering the market, combined with
strategies to supply the generic drugs with the lowest prices. In
addition to this, the guidance of physicians and raising medical
awareness in the general public are required to increase patient
and healthcare system confidence in the capability of generic
medicines in fighting chronic diseases.
LIMITATIONS OF THE STUDY
A significant limitation of this study is the generalizability
of the results since the sample included only respondents in
Amman. Data showed that our surveyed population had a higher
educational background than was initially hypothesized. Almost
80% of the participants reported having a college degree or higher
(BCs degree 55.2%, MSc degree 6.7%, and PhD 1.8%). The lack
of generalizability to the target population may bias the direction
of our findings. Another limitation in our analyses was that our
50-question survey might have been too long for participants.
However, the lack of definitions, examples, and images of
both generic and branded- drugs in our survey may have led to
misinterpretation by the respondents. Thus, responses may have
varied based on which drug category the respondent believed he
or she was addressing.
AUTHOR CONTRIBUTIONS
All authors made substantial contributions to
conception and design, acquisition of data, or analysis and
interpretation of data; took part in drafting the article or
revising it critically for important intellectual content; agreed
to submit to the current journal; and agreed to be accountable
for all aspects of the work.
CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.
FUNDING
The authors have not received any funding support from
the government and industry.
REFERENCES
Aburjai T, Yousif RO, AlSamydai MJ, Al-Samydai A, AlMamoori F, Azzam H. Protein supplements between consumer’s opinion
and quality control: an applied study in Jordan. Int J Res Pharm Sci, 2019;
10(3):1961–9.
013
Ahmed RR, Streimikiene D, Abrhám J, Streimikis J, Vveinhardt
J. Social and behavioral theories and physician’s prescription behavior.
Sustainability, 2020; 12(8):3379.
Alhabeeb MJ. On consumer trust and product loyalty. Int J
Consum Stud, 2007; 31(6):609–12.
Al-Samydai M, Al-Kholaifeh A, Al-Samydai A. The impact
of social media in improving patient’s mental image towards healthcare
provided by private hospitals’ in Amman/Jordan. Indian J Public Health Res
Dev, 2019; 10(2):491–6.
Al-Samydai MJ, Qrimea IA, Yousif RO, Al-Samydai A, Aldin
MK. The impact of social media on consumers’ health behavior towards
choosing herbal cosmetics. J Crit Rev, 2020; 7(9):1171–6.
Aronsson T, Bergman MA, Rudholm N. The impact of generic
drug competition on brand name market shares–evidence from micro data.
Rev Ind Organ, 2001; 19(4):423–33.
Cohen J. Statistical power analysis for the behavioral sciences.
2nd edition, Academic Press, Cambridge, MA, 1999.
Davari M, Khorasani E, Tigabu BM. Factors influencing
prescribing decisions of physicians: a review. Ethiop J Health Sci, 2018;
28(6):795–804.
Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR,
Dutcher SK, Raofi S, Bohn J, Connolly JG, Fischer MA. Comparative
effectiveness of generic and brand-name medication use: a database study
of US health insurance claims. PLoS Med, 2019; 16(3):e1002763.
Dunne S, Shannon B, Dunne C, Cullen W. A review of the
differences and similarities between generic drugs and their originator
counterparts, including economic benefits associated with usage of generic
medicines, using Ireland as a case study. BMC Pharmacol Toxicol, 2013;
14(1):1–19.
Gallelli L, Palleria C, De Vuono A, Mumoli L, Vasapollo P,
Piro B, Russo E. Safety and efficacy of generic drugs with respect to brand
formulation. J Pharm Pharmacol, 2013; 4(Suppl1):S110.
Guttier MC, Silveira MP, Luiza VL, Bertoldi AD. Factors
influencing the preference for purchasing generic drugs in a Southern
Brazilian city. Rev Saude Publ, 2017; 26:51–9.
Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential
savings from substituting generic drugs for brand-name drugs: medical
expenditure panel survey, 1997–2000. Ann Intern Med, 2005; 142(11):891–
7.
Håkonsen H, Toverud EL. Generic Drug Policies. Encyclopedia
of Pharmacy Practice and Clinical Pharmacy, 2019; 130-138.
Ibrahim MI, Awaisu A. Generic medicines and biosimilars:
impact on global pharmaceutical policy. In: Babar Z (ed.). Global
pharmaceutical policy. Palgrave Macmillan, Singapore, Singapore, pp.
53–72, 2020.
Johnston A, Stafylas P, Stergiou GS. Effectiveness, safety and
cost of drug substitution in hypertension. Br J Clin Pharmacol, 2010;
70(3):320–34.
Keenum AJ, DeVoe JE, Chisolm DJ, Wallace LS. Generic
medications for you, but brand-name medications for me. Res Social Adm
Pharm, 2012; 8(6):574–8.
Kesselheim AS, Gagne JJ, Franklin JM, Eddings W, Fulchino
LA, Avorn J, Campbell EG. Variations in patients’ perceptions and use
of generic drugs: results of a national survey. J Gen Intern Med, 2016;
31(6):609–14.
Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart
MA, Choudhry NK, Shrank WH. Clinical equivalence of generic and
brand-name drugs used in cardiovascular disease: a systematic review and
meta-analysis. JAMA, 2008; 300(21):2514–26.
Kohli E, Buller A. Factors influencing consumer purchasing
patterns of generic versus brand name over-the-counter drugs. South Med
J, 2013; 106(2):155–60.
Mohammadshahi M, Alipouri Sakha M, Zarei L, Karimi M,
Peiravian F. Factors affecting medicine-induced demand and preventive
strategies: a scoping review. Shiraz E-Medical J, 2019; 20(10):e87079.
014
Hajleh et al. / Journal of Applied Pharmaceutical Science 11 (09); 2021: 009-017
Nardi EP, Ferraz MB. Percepção de valor de medicamentos
genéricos em São Paulo, Brasil. Cadernos de Saúde Pública, 2016; 32(2):
e00038715.
Olsson E, Sporrong SK. Pharmacists’ experiences and attitudes
regarding generic drugs and generic substitution: two sides of the coin. Int J
Pharm Pract, 2012; 20(6):377–83.
Quintal C, Mendes P. Underuse of generic medicines in
Portugal: an empirical study on the perceptions and attitudes of patients and
pharmacists. Health policy, 2012; 104(1):61–8.
Rizzo JA, Zeckhauser R. Generic script share and the price of
brand-name drugs: the role of consumer choice. Int J Health Care Finance
Econ, 2009; 9(3):291–316.
Schumock GT, Walton SM, Park HY, Nutescu EA, Blackburn
JC, Finley JM, Lewis RK. Factors that influence prescribing decisions. Ann
Pharmacother, 2004; 38(4):557–62.
Shamim-ul-Haq S, Ahmed RR, Ahmad N, Khoso I, Parmar V.
Factors influencing prescription behavior of physicians. Pharm Innov J,
2014; 3(5):30–5.
Tian Y, Reichardt B, Dunkler D, Hronsky M, Winkelmayer WC,
Bucsics A, Strohmaier S, Heinze G. Comparative effectiveness of branded
vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic
substances: a population-wide cohort study. Sci Rep, 2020; 10(1):1–12.
US Food and Drug Administration. Guidance for industry.
Bioequivalence studies with pharmacokinetic endpoints for drugs
submitted under an ANDA. US Food and Drug Administration, Silver
Spring, MD, 2013. Available via http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatory-Information/Guidanees/UCM377465.pdf
Vogler S. How large are the differences between originator
and generic prices? Analysis of five molecules in 16 European countries.
Farmeconomia, 2012; 13(3S):29–41.
Yousif RO, Al-samydai MJ. Factors influencing woman behavior
to visit dental clinic to improve their smile. Indian J Public Health Res Dev,
2019; 10(2).
How to cite this article:
Hajleh MNA, AL-Samydai A, Aloosi Z, Abuhamdan R,
Naimat SA, Abdelfattah L, Al-Halaseh L. Factors affecting
purchasing behaviors of generic drugs versus originator
counterparts in Jordan. J Appl Pharm Sci, 2021; 11(09):
009–017.
015
Hajleh et al. / Journal of Applied Pharmaceutical Science 11 (09); 2021: 009-017
APPENDIX
Table 1. The questionnaire used in this study.
Section One: Below are some questions related to general information. Please select the appropriate answer
The first part: General information for the study sample. Tick the appropriate answer:
1. Gender:
Male
Female
2. Age:
<30 years
From 30 to 40 years
From 40 to 50 years
>50 years and older
3. Marital Status:
Single
Married
Other
4. Number of family members:
5. Educational level:
High school
Diploma Bachelor’s degree Master’s degree PhD Other
6. Field of study:
Medical sector
Science, engineering, and technology sector
Educational, linguistic, or social sciences or business
Others
7. Place of residence
Amman
Other
Part two: The following are some questions related to medical and health education, please select the appropriate the answer
8. Does anyone of your family members or close acquaintances work in the health sector: Yes
No
9. What is the source of your general information in the health field specifically?
Friends or relatives working in the health sector
Friends or relatives who are not working in the health sector
Social Media
General Internet search
10. Do you have chronic diseases that require permanent treatment (diabetes, hypertension, asthma, ...):
Yes
No
11. Did you know that the generic drug contains the same pharmaceutical composition and has the same pharmaceutical form (syrups,
capsules…...) as the originator drug, but the manufacturer and brand name for it is different?
Yes
No
12. Have you heard about bioequivalence studies:
Yes No
13. Did you know that in Jordan there are seven centers licensed by the institutions to conduct drug studies to compare different alternatives
for the same drug and make sure that they have the same efficiency? Several private and government hospitals that have obtained
licenses to conduct such studies and their licenses are renewed every 3 years? Yes No
Section Two:
The following is a set of expressions regarding the factors affecting the choice of medicine, (a comparative study between a
generic drug and an originator drug), please choose the appropriate answer after reading the following phrases:
Strongly
agree
Axes and paragraphs
First category: the role of the physician
1. Your doctor directs you toward using the originator drug due to its high quality
2. You feel that the doctor is dealing with only a limited number of originator
pharmaceutical companies exclusively
3. You feel that there is an agreement between the doctor and the neighboring
pharmacies about the medicine that is given to the patient
4. You find that the prescription written by some doctors cannot be read by most
pharmacists
5. You find that the doctor is interested in the name of the active ingredient of the
medicine and does not care about the country of origin, because both have the same
effectiveness
6. You feel that the doctor dispenses the generic drug because it is cheaper than the
originator and to reduce the cost for the patient
7. You feel that the doctor is dispensing the originator drug because it has a higher price
so that the patient feels the extent of the efficiency and effectiveness of the medicine
dispensed to him
Agree
Neutral
Don’t agree
Strongly
don’t agree
016
Hajleh et al. / Journal of Applied Pharmaceutical Science 11 (09); 2021: 009-017
Strongly
agree
Axes and paragraphs
Second category: the role of the pharmacist
8.The pharmacist tells you that the originator drug is more effective than the generic
drug
9. The pharmacist gives you an alternative originator drug in case the drug prescribed
by the doctor is not available without referring to the doctor
10. When the originator drug prescribed by your doctor is not available, you accept the
generic drug that the pharmacist suggests as an alternative
11. You feel that the pharmacist is directing you to buy a specific originator drug
instead of the generic medicine
Third category: effectiveness
12. You find that the originator drug does not generate unwanted
side effects
13. You find that the generic drug generates unwanted side effects
14. You buy the generic drug in case the originator drug is not
available in the pharmacy because you trust the effectiveness of the
generic drug
15. You find that the effectiveness of the generic drug product is
high compared to the originator drug
16. You find it difficult to distinguish the quality and efficacy of the
generic drug from the originator because you got the same results
from both products which treated the same disease
Fourth category: price
17. You find that the price of the generic drug is lower than the
price of the originator drug
18. You find that you have the willingness to pay a higher price to
obtain an originator drug product because of its high quality
19. You prefer to buy generic drugs because their prices are
reasonable
20. You prefer to buy generic drugs even if their prices are high
Fifth category: information
21. You have good information about the effectiveness of generic
drugs as a result of previous experience
22. You review the medical leaflet attached to the drug, which
gave you the conviction that the quality and effectiveness of the
originator drug is more than the generic drug
23. You see that medical leaflet which comes with the originator
drug gives you all warnings before using it
24. You see that medical leaflet which comes with the generic drug
gives you all warnings before using it
Sixth category: the confidence
25. You trust the brand of the generic drug
26. You trust the brand of the originator drug
27. You trust f originator drug-producing companies more than
generic drug-producing companies
28. You seek to search for originator drugs because your confidence
in them is higher than the generic drug
Seventh category: choose a medication
29. The doctor has the primary role in determining the type of drug
I use
30. You find that the doctor makes you feel that using the originator
drug is more effective
31. You feel that the pharmacist motivates you to choose the
originator drug
Agree
Neutral
Don’t agree
Strongly
don’t agree
017
Hajleh et al. / Journal of Applied Pharmaceutical Science 11 (09); 2021: 009-017
Axes and paragraphs
32. You feel that the generic drug is more available in pharmacies
than the originator drug
33. You choose the generic drug because you think it is more
effective than the originator drug
34. You want to get the generic drug because its price is low
compared to the price of the originator drug
35. You have enough information about the originator drug to make
you choose it
36. You have enough information about the generic drug to make
you choose it
37. You trust the originator drug more than the generic drug, which
makes you feel comfortable when it is prescribed to you
Strongly
agree
Agree
Neutral
Don’t agree
Strongly
don’t agree